aiming to mount a challenge to Amgen's $2.3 billion oral psoriasis therapy Otezla (apremilast). BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by ...

The Ned Otezla commercial features a man gaining confidence to go on a date despite his plaque psoriasis, thanks to Otezla ...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...